Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis

Courtney McCracken, Steven Yeh, Kirsten Jenkins, Curtis Travers, Daneka Stryker, Steven Tommasello, Kelly A. Rouster-Stevens, Scott R. Lambert, Sampath Prahalad, Carolyn Drews-Botsch, Sheila T. Angeles-Han

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Aims: Methotrexate (MTX) is standard treatment in pediatric chronic anterior uveitis (CAU). Addition of tumor necrosis factor-α inhibitors (TNFi) is often needed. We describe the timing and risk factors for TNFi use in children with CAU on MTX. Methods: In this retrospective study, we reviewed 51 records, and 46 met inclusion criteria. Primary outcome was the addition of TNFi due to active CAU per Standardization of Uveitis Nomenclature criteria. Time to TNFi and factors associated with their addition were assessed using survival analysis models. Results: Of 46 children treated with MTX for uveitis (36 juvenile idiopathic arthritis-associated uveitis, 10 idiopathic CAU), 72% had ocular complications. MTX was started a median of 5.0 months, and TNFi 43 months from uveitis diagnosis. Kaplan–Meier estimates suggest that cumulatively, 12% (95% CI: 4–23%) start TNFi within 6 months of MTX, 21% (12–37%) within 1 year, and 39% (24–54%) within 2 years. On Cox Proportional Hazard regression analysis, children with idiopathic CAU required TNFi earlier in their uveitis course (at 3 months (Hazard Ratio 6.06; 95% confidence interval (1.25–29.41))). Females appeared less likely to require TNFi early. Children treated in 2012 and later were more likely to receive TNFi earlier than those treated before 2012. Conclusion: Little is known about optimal time to initiate treatment or factors associated with the need to add TNFi in children on MTX. Children with idiopathic CAU and males required TNFi earlier in their course. Factors associated with these potential risk factors for TNFi warrant further investigation.

Original languageEnglish (US)
Pages (from-to)629-639
Number of pages11
JournalEye (Basingstoke)
Issue number4
StatePublished - Apr 1 2019
Externally publishedYes

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems


Dive into the research topics of 'Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis'. Together they form a unique fingerprint.

Cite this